Tolebrutinib是BTK抑制剂,在第三阶段的研究中,NrSPMS的确认残疾进展延迟了31%。 Tolebrutinib, a BTK inhibitor, demonstrated a 31% delay in confirmed disability progression for nrSPMS in a phase 3 study.
Tolebrutinib(BTK抑制剂)在向欧洲创伤和痛苦感应监测系统会议提交的第3阶段研究中显示,不重复的二级渐进性多发性硬化症(nrSPMS)的确认残疾进展延迟了31%。 Tolebrutinib, a BTK inhibitor, showed a 31% delay in confirmed disability progression for non-relapsing secondary progressive multiple sclerosis (nrSPMS) in a phase 3 study, presented at the ECTRIMS conference. 此外,与安慰剂相比,确认的残疾改善率几乎翻了一番。 Additionally, it nearly doubled the rate of confirmed disability improvement compared to placebo. 它还推迟了复发多发性硬化症的恶化,但没有统计意义。 It also delayed worsening in relapsing multiple sclerosis but without statistical significance. 预计2024年底将提交关于该药物的监管报告。 Regulatory submissions for the drug are anticipated in late 2024.